SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Silva Jose Luis)
 

Sökning: WFRF:(Silva Jose Luis) > Syndecan-4 is a mae...

  • Pocas, JulianaUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.,University of Porto (författare)

Syndecan-4 is a maestro of gastric cancer cell invasion and communication that underscores poor survival

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • Proceedings of the National Academy of Sciences (PNAS),2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-509446
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-509446URI
  • https://doi.org/10.1073/pnas.2214853120DOI
  • https://lup.lub.lu.se/record/e1d3d19e-f007-4245-a2bf-29e92cd240c3URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Gastric cancer is a dominating cause of cancer-associated mortality with limited therapeutic options. Here, we show that syndecan-4 (SDC4), a transmembrane pro-teoglycan, is highly expressed in intestinal subtype gastric tumors and that this sig -nature associates with patient poor survival. Further, we mechanistically demonstrate that SDC4 is a master regulator of gastric cancer cell motility and invasion. We also find that SDC4 decorated with heparan sulfate is efficiently sorted in extracellular vesicles (EVs). Interestingly, SDC4 in EVs regulates gastric cancer cell-derived EV organ distribution, uptake, and functional effects in recipient cells. Specifically, we show that SDC4 knockout disrupts the tropism of EVs for the common gastric cancer metastatic sites. Our findings set the basis for the molecular implications of SDC4 expression in gastric cancer cells and provide broader perspectives on the development of therapeutic strategies targeting the glycan-EV axis to limit tumor progression.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Marques, CatarinaUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.,University of Porto (författare)
  • Gomes, CatarinaUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto (författare)
  • Otake, Andreia HanadaUniv Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Canc Estado Sao Paulo, BR-01246000 Sao Paulo, Brazil.;Champalimaud Fdn, Champalimaud Physiol & Canc Programme, P-1400038 Lisbon, Portugal. (författare)
  • Pinto, FilipeUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto (författare)
  • Ferreira, MarianaUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto (författare)
  • Silva, TiagoUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto (författare)
  • Faria-Ramos, IsabelUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto (författare)
  • Matos, RitaUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto (författare)
  • Ribeiro, Ana RaquelUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.,University of Porto (författare)
  • Senra, EmanuelUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.,University of Porto (författare)
  • Cavadas, BrunoUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.,University of Porto (författare)
  • Batista, SilviaChampalimaud Fdn, Champalimaud Physiol & Canc Programme, P-1400038 Lisbon, Portugal. (författare)
  • Maia, JoanaChampalimaud Fdn, Champalimaud Physiol & Canc Programme, P-1400038 Lisbon, Portugal. (författare)
  • Macedo, Joana A.Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto (författare)
  • Lima, LuisPortuguese Oncol Inst Porto IPO Porto, Res Ctr IPO Porto CI IPOP RISE CI IPOP, Hlth Res Network, Expt Pathol & Therapeut Grp, P-4200072 Porto, Portugal.,Instituto Português de Oncologia do Porto Francisco Gentil (IPO) (författare)
  • Afonso, Luis PedroPortuguese Oncol Inst Porto IPO Porto, Res Ctr IPO Porto CI IPOP RISE CI IPOP, Hlth Res Network, Expt Pathol & Therapeut Grp, P-4200072 Porto, Portugal.,Instituto Português de Oncologia do Porto Francisco Gentil (IPO) (författare)
  • Ferreira, José AlexandrePortuguese Oncol Inst Porto IPO Porto, Res Ctr IPO Porto CI IPOP RISE CI IPOP, Hlth Res Network, Expt Pathol & Therapeut Grp, P-4200072 Porto, Portugal.,Instituto Português de Oncologia do Porto Francisco Gentil (IPO) (författare)
  • Santos, Lúcio LaraPortuguese Oncol Inst Porto IPO Porto, Res Ctr IPO Porto CI IPOP RISE CI IPOP, Hlth Res Network, Expt Pathol & Therapeut Grp, P-4200072 Porto, Portugal.,Instituto Português de Oncologia do Porto Francisco Gentil (IPO) (författare)
  • Polónia, AntónioUniversity of Porto (författare)
  • Osório, HugoUniv Porto, FMUP Fac Med, P-4200319 Porto, Portugal.,University of Porto (författare)
  • Belting, MattiasUppsala University,Lund University,Lunds universitet,Uppsala universitet,Neuroonkologi och neurodegeneration,Science for Life Laboratory, SciLifeLab,Lund Univ, Dept Clin Sci, Sect Oncol, S-22184 Lund, Sweden; Skane Univ Hosp, S-22185 Lund, Sweden,Tumörmikromiljön,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Tumor microenvironment,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)medk-mbe (författare)
  • Reis, Celso A.Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.;Univ Porto, FMUP Fac Med, P-4200319 Porto, Portugal.,University of Porto (författare)
  • Costa-Silva, BrunoChampalimaud Fdn, Champalimaud Physiol & Canc Programme, P-1400038 Lisbon, Portugal. (författare)
  • Magalhães, AnaUniv Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.,University of Porto (författare)
  • Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.University of Porto (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Proceedings of the National Academy of Sciences of the United States of America: Proceedings of the National Academy of Sciences (PNAS)120:200027-84241091-6490

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy